Denmark Patent System

Novo Nordisk A/S (Bagsværd, Copenhagen; Nasdaq: NVO and Nasdaq Copenhagen; market cap ~$500–600B 2024, briefly surpassing LVMH as Europe's most valuable company): Novo Nordisk is the world's leading pharmaceutical company in diabetes and obesity treatment, and in 2023–2024 became one of the most commercially significant patent holders on earth due to the global demand surge for GLP-1 receptor agonist drugs. The GLP-1 (glucagon-like peptide-1) patent strategy: (1) Semaglutide — the core asset: semaglutide is a GLP-1 receptor agonist (peptide drug) with a long-acting fatty acid chain modification enabling once-weekly subcutaneous injection. Novo Nordisk's semaglutide compound patents and formulation patents are filed primarily at the European Patent Office, USPTO, and Japanese Patent Office. Core patents include: semaglutide compound patent (structural analog of human GLP-1 with specific substitution pattern and C18 fatty acid chain; expires 2026–2033 in various jurisdictions); semaglutide formulation patents (aqueous injection pen formulation stabilizers, preservatives — phenol/m-cresol, isotonic agents); semaglutide method-of-treatment patents (glycemic control in type 2 diabetes + cardiovascular risk reduction; SELECT trial data 2023 significantly extended the commercial justification for IP protection of cardiovascular indications); (2) Ozempic vs. Wegovy: semaglutide is sold as Ozempic (0.5 mg and 1 mg, approved FDA 2017) for type 2 diabetes management and Rybelsus (oral semaglutide tablets) — and as Wegovy (2.4 mg, approved FDA June 2021) for chronic weight management. Wegovy's obesity indication is protected by separate method-of-treatment patents (obesity + BMI reduction indication) beyond the Ozempic diabetes indication; (3) Oral semaglutide (Rybelsus): Novo Nordisk developed an oral GLP-1 formulation using SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) absorption enhancer technology. The SNAC-enabled oral peptide absorption patents are commercially critical and represent a separate IP dimension from injectable semaglutide; (4) Compounding controversy: the unprecedented demand for Ozempic/Wegovy in 2023–2024 led to widespread drug shortages; FDA placed compounded semaglutide on its shortage list; compounding pharmacies produced copies; Novo Nordisk has aggressively enforced its IP against unauthorized compounders; (5) Patent expiry landscape: semaglutide compound patents begin expiring circa 2026 in some jurisdictions; Novo Nordisk is investing in next-generation obesity treatments (CagriSema — semaglutide + cagrilintide combination; amycretin oral small molecule GLP-1/GIP) to maintain leadership; (6) Liraglutide (Victoza/Saxenda): earlier-generation GLP-1 agonist; Victoza approved FDA 2010 for T2D; Saxenda 3.0 mg approved 2014 for obesity; key patents largely expired or near expiry 2020s; biosimilar development by Teva, Dr. Reddy's, and others underway. Novo Nordisk holds thousands of patents in diabetes, obesity, hemophilia, and growth disorders; files primarily EPO + USPTO. Novo Nordisk's market capitalization exceeding $500B reflects the commercial value of its GLP-1 patent portfolio combined with manufacturing capacity (Kalundborg, Denmark — world's largest insulin production site; ~40% of world's insulin; major semaglutide fill-finish capacity investment 2022–2025 to address supply constraint).

Ørsted A/S (Fredericia; Nasdaq Copenhagen; ~$30–50B market cap; formerly DONG Energy — renamed Ørsted 2017 after restructuring to focus on offshore wind; Danish state holds ~50.1%): Ørsted is the world's largest developer of offshore wind energy and holds a significant portfolio of offshore wind technology patents. Key patent domains: (1) Monopile foundation design: offshore wind turbines in water depths up to ~35m are typically installed on monopile foundations — steel cylinder piles driven into the seabed. Ørsted (via its technical collaboration with engineering consultancies and turbine manufacturers) holds patents on monopile geometry optimization for different seabed conditions, scour protection system integration, and corrosion protection coating systems; (2) Offshore array cable routing and installation: submarine HVAC array cables interconnecting turbines in offshore wind farms; cable burial and protection systems; dynamic cable connectors; cable fault monitoring systems; (3) Offshore wind farm control systems: wake optimization algorithms (computing optimal yaw angles and curtailment strategies for individual turbines within an array to maximize whole-farm energy output — the turbine wake effect can significantly reduce downwind turbine output); (4) Hornsrev, Hornsea, and other landmark projects: Ørsted's Hornsrev 1 (2002 — world's first large-scale offshore wind farm, 160 MW off Danish coast) and subsequent Hornsea 1 (UK, 1.2 GW, world's largest at completion 2019) and Hornsea 2 (1.3 GW, 2022) are landmark projects generating valuable operational data that informs proprietary process knowledge (not all patented); (5) Vestas Wind Systems (Aarhus; Nasdaq Copenhagen; ~$20–30B market cap): Vestas is the world's largest wind turbine manufacturer (onshore and offshore); blade aerodynamic design patents (airfoil cross-section patents using CFD optimization for maximum lift-to-drag ratio across wind speed range); individual pitch control (IPC) patents for reducing blade fatigue loads; Vestas offshore monopile installation method patents; Vestas gearbox and drivetrain patents. The Danish offshore wind sector is structured around Ørsted (developer), Vestas (turbine OEM), Siemens Gamesa (Copenhagen subsidiary of German Siemens AG — competing turbine OEM; 14+ MW direct-drive offshore turbine patents), and an ecosystem of specialized offshore installation vessel operators (A2SEA, DEME) and cable manufacturers (NKT, Prysmian). Danish offshore wind IP has been widely licensed and transferred internationally through project agreements, turbine supply contracts, and technology licensing.

Grundfos Holding A/S (Bjerringbro, Jutland; private, owned by Poul Due Jensen Foundation; ~$4–5B annual revenue; founded 1945; world's largest pump manufacturer): Grundfos designs and manufactures pumps and pump systems for building services (heating/cooling/hot water), water supply and treatment, industrial processes, and wastewater. Key patent domains: (1) iGRUNDFOS/Grundfos GO intelligent pump management: IoT connectivity patents for remote pump monitoring, predictive maintenance (vibration/temperature anomaly detection), and energy optimization; app-based pump configuration patents; (2) Magnarotor technology: electronically commutated (EC) permanent magnet motor integrated with pump impeller in a waterproof rotor-stator assembly — wet-runner motor design patents; energy efficiency Class IE3/IE4 rating patents; (3) Variable speed drive (VSD) pump control: GRUNDFOS AutoAdapt and AUTOADAPT proportional pressure control patents for HVAC pump systems (adjusting pump speed to maintain system pressure proportional to demand, reducing energy consumption by 50–70% vs. constant speed pumps); (4) Booster system patents: vertical multistage centrifugal pump booster for building water pressure; compact module design and corrosion-resistant material selection patents. Coloplast A/S (Humlebæk; Nasdaq Copenhagen; ~$20B market cap): medical devices for ostomy, urology, wound care, and interventional urology. Coloplast's SenSura Mio ostomy bag patents (convex baseplate design for peristomal skin folds; patented adhesive formulation), Coloplast Assura system, catheter tip design patents. Haldor Topsoe (now Topsoe A/S, Lyngby; Nasdaq Copenhagen; catalysis for ammonia synthesis, sulfur removal, hydrogen production, and SAF [Sustainable Aviation Fuel]): iron-based Haber-Bosch ammonia synthesis catalyst patents; TIGAS synthetic gasoline from methanol patents; green hydrogen electrolysis + Power-to-X; Topsoe BlueThermal™ catalyst for nitrous oxide [N2O] destruction. Chr. Hansen (now dsm-firmenich Biosciences; fermentation microorganism culture patents for dairy [cheese, yogurt] and probiotics; Lactobacillus and Bifidobacterium strain IP). Novozymes (now Novonesis after merger with Chr. Hansen 2023; Bagsværd; world's largest industrial enzyme company; ~$20B market cap): enzyme patent portfolio for laundry detergent [Savinase protease/Lipolase lipase — washing at lower temperatures = energy saving], biofuel cellulose ethanol production [Cellic CTec series cellulase enzymes], food processing [Flavourzyme, Novamyl amylase for bread softening], animal feed [Phytase enzyme for phosphorus bioavailability, reducing feed waste]. Danish IP ecosystem: DTU (Technical University of Denmark), Copenhagen University, AAU (Aalborg University) — research patent pipelines in wind energy, biotech, pharmaceuticals, and sustainable chemistry.

The UPC Nordic-Baltic Division (officially located in Copenhagen) is the Unified Patent Court regional division that covers six countries: Denmark, Finland, Sweden, Estonia, Latvia, and Lithuania. This means that a single UPC case heard in Copenhagen can result in a judgment (including injunction or revocation) that is enforceable in all six Nordic-Baltic countries simultaneously. The Nordic-Baltic Division is one of the UPC's regional groupings, distinct from the local divisions in individual countries (Germany has multiple local divisions, France has Paris, Netherlands has The Hague, Italy has Milan and Rome, etc.). Key implications: (1) A Unitary Patent automatically covers all six Nordic-Baltic countries as well as all other UPC participating states in one right; (2) Patent holders with Unitary Patents do not need to separately validate European patents in Denmark, Finland, Sweden, Estonia, Latvia, and Lithuania — the Unitary Patent covers all simultaneously; (3) UPC infringement proceedings for infringement in Denmark, Finland, or Sweden can be brought in the Nordic-Baltic Division in Copenhagen rather than in separate national courts in each country; (4) However, non-UPC countries in the region remain outside this system: Norway is EPC member but NOT EU and NOT UPC (UPC is EU-only); Iceland is EPC member but not EU and not UPC; Greenland (autonomous territory of Denmark) is not covered by EU IP law. For patent holders with pan-Scandinavian market interests, the Unitary Patent + Nordic-Baltic Division is commercially attractive because it replaces the need for separate national EP validations and separate national court proceedings in each country.

Novo Nordisk's semaglutide IP strategy is built around multiple layers of protection: (1) Compound patent: the semaglutide molecule itself (a GLP-1 receptor agonist with specific amino acid substitutions and C18 fatty acid chain modification enabling once-weekly dosing) is protected by a core compound patent that expires at different dates in different jurisdictions. In the US, the base semaglutide compound patent is expected to expire in the mid-2020s to early 2030s depending on the specific claim and whether PTE/SPC extensions apply. The uncertainty in expiry dates is because (a) Novo Nordisk has multiple patent families covering different aspects of the molecule, (b) SPC extensions in the EU extend exclusivity by up to 5 years, and (c) litigation outcomes affect effective protection; (2) Formulation patents: patents covering the specific injectable formulation (buffer, preservative, isotonicity agents, pH) used in Ozempic and Wegovy autoinjector pens represent a second protection layer beyond the compound patent; (3) Method-of-treatment patents: the obesity/weight management indication for Wegovy (2.4 mg) is covered by separate method-of-treatment patents for chronic weight management in obese or overweight patients, distinct from the diabetes treatment indication of Ozempic; (4) SELECT trial data: the SELECT cardiovascular outcomes trial (NEJM 2023) showed semaglutide 2.4 mg significantly reduced major adverse cardiovascular events (MACE) in non-diabetic obese patients; the cardiovascular indication data supports a new method-of-treatment patent for cardiovascular risk reduction in obesity; (5) Oral semaglutide / Rybelsus: the SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) absorption enhancer technology enabling oral GLP-1 absorption has its own patent family (SNAC was originally developed by Emisphere Technologies, licensed to Novo Nordisk); (6) Compounding: the FDA's shortage list placement of semaglutide created a legal window for compounding pharmacies. Novo Nordisk has actively enforced its patents against commercial-scale compounders. FDA removed compounded semaglutide from the shortage list in late 2024 as supply improved, ending much of the compounding window. Generic semaglutide entry is expected to begin shortly after compound patent expiry — though the complex peptide manufacturing and formulation IP provides additional barriers to entry beyond the base compound patent.

Denmark's offshore wind IP is distributed across several types of actors: (1) Turbine manufacturers (OEMs) hold the core aerodynamic, mechanical, and electrical patents: Vestas Wind Systems (Aarhus) — blade aerodynamic design patents (airfoil cross-section optimization), individual pitch control (IPC) for load reduction, variable-speed gearbox and drivetrain patents, power converter patents, control system software patents; Siemens Gamesa Renewable Energy (SGRE, partly based in Copenhagen after merger of Siemens Wind Power + Gamesa 2017) — direct-drive permanent magnet generator patents (eliminating gearbox for offshore turbines above 10 MW), offshore nacelle craneability patents (access in offshore conditions), DTU-Siemens Gamesa collaborative blade research patents; (2) Foundation and installation: Ørsted and its engineering contractors hold patents on monopile foundation geometry optimization; DEME (Belgian) and Heerema hold offshore installation vessel patents; Bladt Industries (Aalborg) holds offshore foundation structural fabrication patents; (3) Interconnection and cabling: NKT A/S (formerly NKT Cables, Brøndby; Nasdaq Copenhagen) — subsea HVDC and HVAC cable design and installation method patents; dynamic cable connector patents for floating offshore wind; (4) Floating offshore wind: the transition to floating offshore wind (beyond 60m water depth) involves new IP from Norwegian companies (Equinor Hywind spar-buoy patents), Dutch companies (MARIN marine research), and Danish research institutions (DTU Wind Energy). Ørsted and Vestas have both entered the floating wind market with new technology investments; (5) Wake optimization / digital wind farm management: Siemens Digital Industries, ABB, and various software companies hold SCADA and control optimization patents for maximizing energy yield from offshore wind farms; (6) Key fact about Vestas: Vestas is the world's largest wind turbine manufacturer by installed capacity (as of 2023). Vestas holds thousands of patents filed primarily at EPO and USPTO. Vestas has been involved in significant patent litigation with Siemens/SGRE and others over blade design and control system patents.

The Danish utility model (brugsmodel) is a registered IP right providing 10-year protection for the shape, structure, or configuration of a product: (1) Term and renewal: 10 years from filing, with possible renewals at 3 and 6 years (maximum 10-year total term); (2) Subject matter: covers the three-dimensional form, structure, or configuration of a physical product. Does NOT cover: processes or methods; chemical compounds or compositions; biological materials; inventions that are only distinguished from prior art by their purpose. This subject matter limitation is similar to utility models in Germany (Gebrauchsmuster), Japan (Jitsuyou Shin-an), and the Czech Republic (vzor užitný); (3) Examination: DKPTO registers the utility model after a formal requirements check but WITHOUT conducting a full substantive examination for inventive step. The prior art search is conducted but the determination of obviousness/non-obviousness is not made at registration. This makes the utility model faster (typically 6–12 months) and cheaper than a full invention patent (20-year term, 3–5 year examined prosecution); (4) Enforcement: a Danish utility model carries a weaker presumption of validity than a fully examined invention patent. In litigation, the defendant will almost always challenge the utility model's validity on inventive step grounds. The utility model is useful for obtaining registered protection quickly while a full invention patent application is pending; (5) Comparison with Swedish and Norwegian practice: Sweden and Norway do NOT have utility model systems; Denmark and Finland do. This creates an interesting regional divergence within the Nordic countries — Danish and Finnish companies have a utility model option that Swedish and Norwegian companies lack for domestic protection; (6) Dual filing: an applicant can simultaneously file both a Danish utility model and a Danish patent application (or EPO application) for the same invention. The utility model provides faster registered protection; the full patent provides the stronger, longer-term protection once examined.

Denmark joined the London Agreement on the application of Article 65 EPC (which came into force May 1, 2008), which significantly reduces the cost of validating European Patent Office (EPO) grants in Denmark. Here is how the London Agreement affects EP validation in Denmark specifically: (1) Without London Agreement (pre-2008, or for countries that have not joined): after an EPO patent is granted, the patent holder must translate the full patent specification into the national language of each country where they want national validation within 3 months of grant. For Denmark, this would have meant translating the entire patent into Danish — a cost of several thousand EUR per patent for a typical 20–50 page specification; (2) With London Agreement (post-2008): for Denmark, if the EPO patent is granted in English (the most common EPO grant language), only the patent claims need to be translated into Danish — the full description and figures do not need a Danish translation. For patents granted in French or German (less common), the full specification must be translated into English (which Denmark has agreed to accept) plus Danish-language claims; (3) Cost savings: the London Agreement reduced Danish EP validation costs by an estimated 50–80% for English-language grants. This makes Denmark cheaper to include in EP bundle coverage than non-London Agreement states; (4) Comparison with Norway: Norway is NOT a London Agreement signatory (Norway is EPC member but not EU; the London Agreement is an EPC-related agreement that Norway chose not to join). This means Norway requires full Norwegian translation of EP specifications for Norwegian validation — a higher cost than Denmark. Companies filing EP bundle patents must decide whether to include Norway at its higher translation cost; (5) Novo Nordisk and Vestas strategy: for companies with large EP patent portfolios like Novo Nordisk and Vestas, the London Agreement's cost reduction means it is economical to routinely include Denmark in EP validations. This ensures comprehensive Danish/Nordic protection for their key innovations at manageable cost.